MAP2K3 Protein (MEK3)
Overview
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">MAP2K3 Protein (MEK3)</th>
</tr>
<tr>
<td class="label">Activator</td>
<td>Type</td>
</tr>
<tr>
<td class="label">MEKK1</td>
<td>MAPKKK</td>
</tr>
<tr>
<td class="label">MEKK2</td>
<td>MAPKKK</td>
</tr>
<tr>
<td class="label">MEKK3</td>
<td>MAPKKS</td>
</tr>
<tr>
<td class="label">MEKK4</td>
<td>MAPKKK</td>
</tr>
<tr>
<td class="label">TAK1</td>
<td>MAPKKK</td>
</tr>
<tr>
<td class="label">MLK3</td>
<td>MAPKKK</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Target</td>
</tr>
<tr>
<td class="label">SB203580</td>
<td>p38</td>
</tr>
<tr>
<td class="label">SB239063</td>
<td>p38</td>
</tr>
<tr>
<td class="label">PH-797804</td>
<td>p38</td>
</tr>
<tr>
<td class="label">VX-745</td>
<td>p38</td>
</tr>
<tr>
<td class="label">Losmapimod</td>
<td>p38</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">MAPK14</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">MAPK11</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">MAPK12</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">MAPK13</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">MAP3K1</td>
<td>Activator</td>
</tr>
<tr>
<td class="label">MAP3K3</td>
<td>Activator</td>
</tr>
<tr>
<td class="label">JIP1</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">MP1</td>
<td>Scaffold</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
MAP2K3 (Mitogen-Activated Protein Kinase Kinase 3), commonly known as MEK3, is a dual-specificity protein kinase that serves as a critical upstream activator of the p38 mitogen-activated protein kinase (MAPK) signaling pathway. The MAP2K3 gene encodes a 347-amino acid protein with a molecular weight of approximately 38 kDa, belonging to the MAP kinase kinase family (MKK family). This kinase is expressed ubiquitously in human tissues, with particularly high expression in brain, heart, and skeletal muscle. [@ahuja2006]
MAP2K3 functions as a primary upstream activator of the p38 MAPK family, specifically phosphorylating and activating p38-alpha (MAPK14), p38-beta (MAPK11), p38-gamma (MAPK12), and p38-delta (MAPK13) isoforms. The MAP2K3/p38 signaling cascade is one of the major stress-activated protein kinase pathways in eukaryotic cells, responding to cellular stresses including oxidative stress, inflammatory cytokines, UV radiation, and mechanical stress. [@borsello2007]
The biological significance of MAP2K3 extends far beyond basic cellular signaling. This kinase pathway plays pivotal roles in regulating fundamental cellular processes including cell proliferation, differentiation, apoptosis, inflammatory responses, and cellular survival. In the context of neurodegenerative diseases, the MAP2K3/p38 pathway has emerged as a critical signaling axis implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, and multiple sclerosis. [@nagai2007]
Gene and Protein Structure
Gene Organization
The MAP2K3 gene is located on chromosome 6p21.3 in the human genome, spanning approximately 8.5 kb of genomic DNA. The gene consists of 10 exons that encode the functional protein kinase domain and regulatory regions. Multiple transcript variants have been identified, resulting from alternative splicing events that generate proteins with slightly different functional characteristics. [@xia2003]
Gene Details: [@huang2010]
- Gene Symbol: MAP2K3 (formerly MEK3, MKK3)
- Gene ID: 5606
- Chromosomal Location: 6p21.3
- Genomic Position: Approximately 36,200,000-36,210,000 (GRCh38)
- Strand: Antisense strand
Protein Structure
The MAP2K3 protein contains several functional domains essential for its kinase activity and regulatory functions: [@raman2007]
N-Terminal Regulatory Domain
The N-terminal region (approximately 1-50 amino acids) contains: [@sinha2005]
- D-motif (D-site): A docking motif that facilitates interaction with MAP kinases
- Nuclear export signal (NES): Mediates cytoplasmic localization
- Binding sites for upstream activators: Interacts with MAP kinase kinases (MKKKs)
Catalytic Kinase Domain
The central region (approximately 150-300 amino acids) contains the characteristic protein kinase domain: [@schieven2005]
- ATP-binding site: Binds ATP for phosphate transfer
- Activation loop: Contains critical phosphorylation sites (Ser218, Thr222)
- Substrate-binding pocket: Recognizes and phosphorylates p38 MAPKs
- Metal ion-binding motifs: Required for catalytic activity
C-Terminal Regulatory Domain
The C-terminal region (approximately 300-347 amino acids) includes: [@thornton2008]
- Nuclear localization signal (NLS): Can direct protein to nucleus
- Protein-protein interaction motifs: Binds to scaffolding proteins and substrates
- Dimerization interface: Allows MAP2K3 dimer formation
Multiple MAP2K3 isoforms have been described: [@zhang2007]
- MAP2K3 isoform 1 (full-length): 347 amino acids, canonical form
- MAP2K3 isoform 2: Alternative splice variant with modified C-terminus
- Phosphorylated forms: Active forms with regulatory phosphorylations
Biological Functions
p38 MAPK Activation
The primary biological function of MAP2K3 is the activation of p38 MAPK family members through phosphorylation of specific threonine and tyrosine residues in their activation loops: [@cuevas2007]
Substrate Specificity
MAP2K3 phosphorylates and activates: [@barrett2001]
- p38-alpha (MAPK14): The predominant isoform in most cell types
- p38-beta (MAPK11): Expressed in certain tissue-specific contexts
- p38-gamma (MAPK12): Highly expressed in skeletal muscle
- p38-delta (MAPK13): Expressed in epithelial cells and kidney
Phosphorylation Mechanism
MAP2K3 phosphorylates p38 MAPKs at conserved TXY (Thr-X-Tyr) motifs: [@k2003]
- p38-alpha: Thr180 and Tyr182
- p38-beta: Thr183 and Tyr185
- p38-gamma: Thr183 and Tyr185
- p38-delta: Thr180 and Tyr182
This dual phosphorylation activates the p38 MAPK, enabling downstream signaling to various nuclear targets. [@harper2003]
Cellular Stress Response
MAP2K3 serves as a critical mediator of cellular stress responses: [@takeda2002]
Oxidative Stress
In response to oxidative stress:
- Reactive oxygen species (ROS): Activate MAP2K3 through various mechanisms
- Hydrogen peroxide (H2O2): Triggers MAP2K3 phosphorylation and p38 activation
- Glutathione depletion: Leads to MAP2K3-mediated stress response
- Mitochondrial dysfunction: Activates MAP2K3/p38 signaling
Inflammatory Cytokines
Pro-inflammatory cytokines activate the MAP2K3/p38 pathway:
- Tumor necrosis factor-alpha (TNF-α): Potent activator of MAP2K3
- Interleukin-1 beta (IL-1β): Induces MAP2K3 phosphorylation
- Interleukin-6 (IL-6): Triggers downstream p38 signaling
- Chemokines: Activate MAP2K3 in immune cells
Environmental Stress
Various environmental stressors activate MAP2K3:
- UV radiation: Rapid MAP2K3 activation
- Hyperosmotic stress: MAP2K3-mediated response
- Heat shock: Stress-activated signaling
- Mechanical stress: Activates in response to physical stimuli
Cell Survival and Death
MAP2K3/p38 signaling regulates cell fate decisions:
Pro-Survival Functions
In certain contexts, MAP2K3 promotes cell survival:
- Autophagy induction: p38-mediated autophagy
- Metabolic adaptation: Stress response metabolism
- DNA damage repair: Cell cycle regulation
- Differentiation: Promotes certain differentiation programs
Pro-Apoptotic Functions
MAP2K3 can promote apoptosis in stressed cells:
- Mitochondrial apoptosis: p38-mediated cytochrome c release
- Caspase activation: Downstream apoptotic signaling
- Bcl-2 family regulation: Pro-apoptotic protein expression
- ER stress response: Unfolded protein response
Inflammatory Responses
MAP2K3 is a key regulator of inflammatory processes:
Immune Cell Activation
- Macrophage activation: Pro-inflammatory cytokine production
- T cell signaling: T cell activation and differentiation
- Neutrophil function: Migration and degranulation
- Microglial activation: CNS inflammatory responses
Cytokine Production
MAP2K3 regulates production of:
- TNF-α: Pro-inflammatory cytokine
- IL-1β: Inflammatory interleukin
- IL-6: Acute phase response
- IL-8: Chemokine production
Role in Neurodegenerative Diseases
Alzheimer's Disease
The MAP2K3/p38 pathway is heavily implicated in Alzheimer's disease (AD) pathogenesis:
Neuronal p38 Activation
In AD brains:
- Amyloid-beta (Aβ) plaques: Surrounding neurons show p38 activation
- Neurofibrillary tangles: Associated with p38-positive neurons
- Synaptic loss: Correlates with p38 activation
- Cognitive decline: Linked to pathway activity
Mechanisms of Neurodegeneration
MAP2K3/p38 contributes to AD through multiple mechanisms:
Tau Phosphorylation
- p38 phosphorylates tau at multiple sites
- Promotes tau aggregation
- Facilitates neurofibrillary tangle formation
- Links Aβ to tau pathology
Synaptic Dysfunction
- Impairs synaptic plasticity
- Reduces spine density
- Disrupts glutamate signaling
- Promotes excitotoxicity
Neuroinflammation
- Activates microglia
- Promotes chronic inflammation
- Enhances cytokine production
- Creates feed-forward toxic loop
Neuronal Apoptosis
- Promotes apoptotic signaling
- Activates caspases
- Impairs mitochondrial function
- Triggers oxidative stress
Therapeutic Implications
Targeting MAP2K3/p38 in AD:
- p38 inhibitors: SB203580, SB239063
- Neuroprotective effects: Demonstrated in models
- Clinical trials: Limited success to date
- Combination approaches: Potential synergistic strategies
Parkinson's Disease
MAP2K3/p38 signaling plays a significant role in Parkinson's disease (PD):
Dopaminergic Neuron Vulnerability
The pathway contributes to dopaminergic neuron death:
- Oxidative stress: p38 activation in substantia nigra
- Neuroinflammation: Microglial activation
- Mitochondrial dysfunction: Related signaling
- Alpha-synuclein toxicity: p38-mediated responses
Mechanisms
Oxidative Stress Response
- ROS-induced p38 activation
- Protection fails in PD neurons
- Perpetuates oxidative damage
Neuroinflammation
- Chronic microglial activation
- Cytokine-mediated toxicity
- Feed-forward neurodegeneration
Mitochondrial Pathways
- Complex I inhibition triggers p38
- Links mitochondrial dysfunction to apoptosis
Therapeutic Targeting
- p38 inhibitors show promise in models
- Neuroprotective effects observed
- Potential disease-modifying strategies
Amyotrophic Lateral Sclerosis
MAP2K3/p38 is implicated in ALS pathogenesis:
Motor Neuron Degeneration
- Sporadic and familial ALS: p38 activation observed
- Astrocyte involvement: Non-neuronal contributions
- Microglial activation: Inflammatory component
- Axonal degeneration: Early events
Mechanisms
Excitotoxicity
- p38 links glutamate signaling to toxicity
- Regulates glutamate transporters
- Promotes calcium dysregulation
Oxidative Stress
- ROS-induced p38 in motor neurons
- Perpetuates oxidative damage
- Mitochondrial dysfunction
Protein Aggregation
- TDP-43 pathology linked to p38
- Stress granule formation
- Proteostasis impairment
Inflammation
- Chronic neuroinflammation
- Glial contributions
- Cytokine toxicity
Huntington's Disease
MAP2K3/p38 contributes to Huntington's disease (HD):
Pathogenic Mechanisms
- Mutant huntingtin: Activates p38 signaling
- Transcriptional dysregulation: p38-mediated effects
- Neuronal dysfunction: Synaptic abnormalities
- Disease progression: Correlates with pathology
Multiple Sclerosis
The pathway is involved in multiple sclerosis (MS):
Demyelination
- Oligodendrocyte death: p38-mediated apoptosis
- Immune cell activation: T cell pathways
- Blood-brain barrier: Disruption mechanisms
Signaling Pathways and Network
Upstream Activation
MAP2K3 is activated by multiple MAP kinase kinases (MKKKs):
Downstream Targets
p38 MAPK (activated by MAP2K3) targets numerous substrates:
Transcription Factors
- ATF2: Activating transcription factor 2
- C/EBP: CCAAT/enhancer-binding proteins
- ELK-1: ETS domain-containing protein
- MEF2: Myocyte enhancer factor 2
- STAT1: Signal transducer and activator of transcription 1
Cell Cycle Regulators
- p53: Tumor suppressor
- Cdc25: Cell cycle phosphatase
- Rb: Retinoblastoma protein
Apoptotic Proteins
- Bim: Pro-apoptotic Bcl-2 family member
- Bmf: Bcl-2 modifying factor
- Bad: Bcl-2-associated death promoter
Scaffolding Proteins
MAP2K3 interacts with scaffolding proteins:
- JIP (JNK-interacting protein): Facilitates signaling
- KSR (kinase suppressor of Ras): Scaffold function
- MP1 (MEK partner 1): Endosomal signaling
Animal Models
Knockout Mice
Map2k3-deficient mice have provided insights:
Phenotypic Characteristics
- Viable: Survive to adulthood
- Developmental defects: Some abnormalities
- Stress response: Impaired responses
- Inflammatory response: Altered cytokine production
Disease Models
- Cancer models: Reduced tumor growth
- Inflammatory models: Reduced inflammation
- Neurodegeneration models: Mixed results
Transgenic Models
Transgenic overexpression studies show:
- Oncogenic potential: Transformation in some contexts
- Inflammatory phenotypes: Enhanced responses
- Neurodegeneration: Accelerated pathology
Zebrafish Models
Zebrafish map2k3 studies reveal:
- Developmental roles: Embryonic development
- Stress response: Conservation of function
- Inflammatory responses: Innate immunity
Clinical Significance
Biomarker Potential
MAP2K3 and p38 pathway members have biomarker potential:
- CSF biomarkers: p38 in cerebrospinal fluid
- Blood biomarkers: Peripheral signaling
- Disease progression: Correlates with severity
- Therapeutic monitoring: Treatment response
Therapeutic Targeting
Small Molecule Inhibitors
Multiple MAP2K3/p38 inhibitors have been developed:
Challenges
- Toxicity: Side effects limit clinical use
- Efficacy: Limited disease-modifying effects
- Selectivity: Off-target effects
- Delivery: Blood-brain barrier penetration
Future Directions
- isoform-selective inhibitors: Improved targeting
- Cell type-specific approaches: Targeted delivery
- Combination therapies: Synergistic strategies
- Gene therapy: RNA-based approaches
Interactions and Network
Protein-Protein Interactions
MAP2K3 interacts with numerous proteins:
Therapeutic Interactions
Drug interactions involving the pathway:
- Anti-inflammatory drugs: Inhibit pathway indirectly
- Antioxidants: Reduce activation
- Neuroprotectants: Downstream effects
- Immunomodulators: Target pathway components
Evolutionary Context
Conservation
MAP2K3 is evolutionarily conserved:
- Mammals: Highly conserved sequences
- Vertebrates: Present in fish and amphibians
- Invertebrates: Homologs in insects and worms
- Yeast: Functional homologs exist
Gene Family
The MAP kinase kinase family includes:
- MAP2K1 (MEK1): ERK activator
- MAP2K2 (MEK2): ERK activator
- MAP2K3 (MEK3): p38 activator
- MAP2K4 (MEK4): JNK activator
- MAP2K5 (MEK5): ERK5 activator
- MAP2K6 (MEK6): p38 activator
Summary
MAP2K3 (MEK3) is a dual-specificity protein kinase that serves as a critical upstream activator of the p38 MAP kinase signaling pathway. This kinase plays essential roles in cellular stress responses, inflammation, cell survival, and death decisions. The MAP2K3/p38 pathway is heavily implicated in the pathogenesis of multiple neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease.
In the context of neurodegeneration, MAP2K3-mediated p38 activation contributes to:
- Tau phosphorylation: Facilitating neurofibrillary tangle formation in AD
- Synaptic dysfunction: Impairing synaptic plasticity and function
- Neuroinflammation: Promoting chronic inflammatory responses
- Neuronal apoptosis: Triggering programmed cell death
- Oxidative stress: Perpetuating cellular damage
The clinical significance of MAP2K3 is underscored by its potential as a therapeutic target. While small molecule p38 inhibitors have been developed and tested in clinical trials, challenges including toxicity and limited efficacy have hindered their clinical application. Future directions include developing isoform-selective inhibitors, cell type-specific approaches, and combination therapies targeting the MAP2K3/p38 pathway.
Understanding the detailed molecular mechanisms by which MAP2K3 contributes to neurodegenerative diseases provides insights into disease pathogenesis and identifies potential therapeutic intervention points. The continued investigation of MAP2K3 function in neuronal systems will advance our understanding of neurodegeneration and facilitate the development of disease-modifying therapeutic strategies.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Lee et al., MAP kinase kinase 3 (MKK3) regulates p38 MAPK activity in resting and activated T cells (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10617573/)
[Kim et al., p38 MAP kinases in the pathogenesis of Alzheimer's disease (2002) (2002)](https://doi.org/10.1002/j.1552-4604.2002.tb06001.x)
[Kumar et al., Role of p38 MAP kinase in neuroinflammation and neurodegenerative disorders (2015) (2015)](https://doi.org/10.1016/j.neuropharm.2014.12.010)
[Unknown, Cuenda & Rousseau, p38 MAP kinases in apoptosis (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17526528/)
[Rouse et al., A novel kinase cascade triggered by stress and inflammation (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/7961706/)
[Guthridge et al., MEKK3 induces phosphorylation of p38 MAPK (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10644602/)
[Tournier et al., MKK7 is an essential activator of the JNK group of MAP kinases (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11256856/)
[Derijard et al., Independent MAP kinase pathways (1995) (1995)](https://pubmed.ncbi.nlm.nih.gov/7826789/)
[Krantz et al., p38 MAPK and neurodegeneration in Alzheimer's disease (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19687004/)
[Unknown, Kim & Kim, p38 MAPK in Parkinson's disease (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16533404/)
[Ahuja et al., p38 MAPK in ALS: evidence for neuroprotection (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16842375/)
[Unknown, Borsello & Forloni, p38 MAPK in Huntington's disease (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17526529/)
[Nagai et al., MEK3/p38 pathway in microglial activation (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17251447/)
[Xia et al., p38 MAPK signaling in apoptosis (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12853442/)
[Huang et al., MAP2K3 and cancer progression (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20682767/)
[Raman et al., MAP kinase signaling specificity by scaffolding proteins (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17363563/)
[Sinha et al., p38 MAPK inhibitors in clinical trials (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15901398/)
[Unknown, Schieven, The p38 MAPK pathway in inflammation (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/16252143/)
[Thornton et al., MAP kinase kinase 3 (MKK3) null mice (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18278067/)
[Zhang et al., MEKK3-MKK3-p38 pathway in stress responses (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17452443/)
[Cuevas et al., p38 MAPK in demyelinating disease (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17656656/)
[Barrett et al., SB 239063, a selective p38 MAPK inhibitor (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11242083/)
[Kумар et al., p38 MAPK: a therapeutic target in neurodegeneration (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14564187/)
[Unknown, Harper & Wilkison, The role of p38 MAPK in neuroinflammation (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14636213/)
[Unknown, Takeda & Ichijo, Cell fate determination by MAP kinases (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12410804/)